NCT01030939View on ClinicalTrials.gov

Study to Investigate Safety, Tolerability, Pharmacokinetics and Cardiac Function After Repeat Doses of SB-649868 in Healthy-volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

72

Participants

Timeline

Start Date

August 27, 2009

Primary Completion Date

January 6, 2010

Study Completion Date

January 6, 2010

Conditions

Sleep Disorders

Interventions

DRUG

SB-649868

In each of all cohorts, 18 subjects will be randomised in a 2:1 ratio to receive either SB-649868 or placebo

Trial Locations (1)

14050

GSK Investigational Site, Berlin

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY